Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93249Research ArticlePrimenenie bisoprolola v praktike kardiologaGendlinG. E-BorisovS. N-MelekhovA. V-151020101210677128122021Copyright © 2010, Consilium Medicum2010[Wellstein A. et al. Concentration kinetics of propranolol, bisoprolol and atenolol in humans assessed with chemical detection anda subtype selective adrenoreceptor. J Cardiovasc Pharmacol 1986; 8 (Suppl): 41.][Brixius K, Bundkirchen A, Bolck B et al. nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001; 133 (8): 1330–8.][Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 16–20.][Horikiri Y, Suzuki T, Mizobe M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci 1998; 87 (3): 289–94.][Leopold G, Kutz K. Bisoprolol: pharmacokinetic profile. Rev Contemp Pharmacother 1997; 8: 35–43.][Руководство по кардиологии: учебное пособиев 3 т. Под ред. Г.И.Сторожакова, А.А.Горбаченкова. М.: ГЭОТАР - Медиа, 2008.][Cheung W.K, Begg E, Dutta A et al. Dose proportionality of bisoprolol in man. Pharm Res 1988; 5 (Suppl.): S159.][Lithell H, Selinus I, Hosie J et al. Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension:a double - blind, parallel group international multicentre study. Eur Heart J 1987; 8 (Suppl. M): 55–64.][Метелица В.И., Дуда С.Г., Горбунов В.М.и др. Антигипертензивный эффект нового кардиоселективного бета - адреноблокатора пролонгированного действия бисопролола по сравнениюс пропранололом, метопрололоми плацебо. Экспер.и клин. фармакол. 1995; 58 (2): 32–4.][Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol:a randomized multicentre double - blind study (BISOMET). Eur Heart J 1987; 8: 103–13.][Benetos A, Adamopoulos C, Argyriadis P et al. Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly J Hypertens 2002; 20 (Suppl. 1): S21–5.][United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.][von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS),a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995; 25 (1): 231–8.][van de Ven L.L, Vermeulen A, Tans J.G et al. Which drug to choose for stable anginapectoris:a comparative study between bisoprolol and nitrates. Int J Cardiol 1995; 47 (3): 217–23.][Yusuf S, Lessem J, Pet J et al. Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertens 1993; 11 (Suppl. 4): 561–73.][de Muinck E.D, Lie K.I von Mengden H.J. Bisoprolol pilot studies in myocardial infarction. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): 5196–200.][Национальные рекомендации ВНОКи ОССН по диагностикеи лечению ХСН (3-й пересмотр). Под ред. Ф.Т.Агеева, Г.П.Арутюнова, В.Ю.Марееваи др. Серд. недостат. 2009; 2: 64–103.][The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text. Eur Heart J 2005; 26.][ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001; 104: 2996–3007.][CIBIS Investigators and Committees. A randomized trial of beta - blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994; 90: 1765–73.][CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomized trial. Lancet 1999; 353: 9–13.][Possible clinical implications of the Cardiac Insufficiency Bisoprolol (CIBIS) III trial. Br J Cardiol 2005; 12: 448–54.][Беленков Ю.Н. Скворцов А.А., Мареев В.Ю.и др. Клинико - гемодинамическиеи нейрогормональные эффекты длительной терапии β - адреноблокатором бисопрололом больныхс тяжелой хронической сердечной недостаточностью. Кардиология 2003; 43 (10): 10–21.][Иваненко В.В. Рязанцева Н.В., Тарасов Д.Л., Лопатин Ю.М. Влияние β1 - адреноблокатора бисопролола на восстановление функции гибернирующего миокардау больныхс хронической сердечной недостаточностью ишемической этиологии. Кардиология 2004; 44 (7): 57–61.][Сторожаков Г.И., Гендлин Г.Е. Основные направленияв лечении больныхс хронической сердечной недостаточностью. Руководство для врачей - терапевтов, врачей общей практики. М.: Миклош, 2008.][Михайлова И.Е., Перепеч Н.Б. Бисопролол: фармакологические свойстваи клиническое применение. Рус. мед. журн. 2004; 12 (4): 225.][Chen J, Redfort M.J, Wang Y et al. Effectiveness of beta - blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 7: 1950–6.][Мелехов А.В. Состояние артериального сосудистого русла, микроциркуляциии биомеханики дыханияу больныхс хронической сердечной недостаточностью. Дис.. канд. мед. наук. М., 2005.][Janka H.U, Ziegler A.G, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin - dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96–9.][Prisant L.M, Weir M.R, Papademetriou V et al. Low - dose drug combination therapy: an alternative first - line approach to hypertension treatment. Am Heart J 1995; 130 (2): 359–66.][Prisant L.M, Weir M.R, Frishmanwh et al. Self reported Sexual Dysfunction in Men and Woman Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens 1999; 1: 22–6.][Cohn J.N, Fowler M.B, Bristow M.B et al. for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997; 3: 173–9.][Packer M, Fowler M.B, Roccker E.B et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.][Ekman M, Zethraeus N, Dahlstrom U, Hoglund C. Cost -effectiveness of bisoprolol in chronic heart failure. Lakartidningen. 2002; 99 (7): 646–50.][Varney S. A cost - effectiveness analysis of bisoprolol for heart failure. Eur J Heart Fail 2001; 3 (3): 365–71.]